Tris(Dibenzylideneacetone)dipalladium(0) (tris dba) abrogates tumor progression in hepatocellular carcinoma and multiple myeloma preclinical models by regulating the stat3 signaling pathway

• Main Authors: Arora, Loukik, Mohan, Chakrabhavi Dhananjaya, Yang, Min Hee, Rangappa, Shobith, Deivasigamani, Amudha, Kumar, Alan Prem, Kunnumakkara, Ajaikumar B., Garg, Manoj, Chinnathambi, Arunachalam, Alharbi, Sulaiman Ali, Alahmadi, Tahani Awad, Rangappa, Kanchugarakoppal S., Hui, Kam Man, Sethi, Gautam, Ahn, Kwang Seok
• 其他作者: PHARMACOLOGY
• 格式: Article
• 出版: MDPI 2022
• 主題: Orthotopic; SHP2; STAT3 signaling inhibitor; Tris DBA; Xenograft
• 在線閱讀: https://scholarbank.nus.edu.sg/handle/10635/232792

10.3390/cancers13215479